Congressman Jim Clyburn (D-SC), Chair of the House Subcommittee on the coronavirus crisis, joined Andrea Mitchell to discuss his committee’s probe into a possible “insider dealing” with respect to Emergent BioSolutions contract with the Trump administration.
Subcommittee is looking at a multi-million dollar contracts given to Emergent BioSolutions by the Trump administration.
Johnson & Johnson vaccine is produced in Baltimore facilities of Emergent BioSolutions.
The U.S. Food and Drug Administration inspected Emergent BioSolutions and “cited a number of observations concerning whether the facility’s processes met our requirements and standards.”
The inspecting came after it was reported that due to “human error” 15 million potential doses of the J&J coronavirus vaccine were ruined.
Clyburn was hopeful that Emergent BioSolutions would cooperate with his Subcommittee and “explain what they’re doing, tell the American people whether or not they consider themselves to be capable of doing this.”
Stocks of Emergent BioSolutions were trading lower at NYSE: EBS 63.12 USD −2.88 (4.36%), almost 50% down from their pick of 125 USD back in February 2021.
- Lebron James Deletes His Post Saying “You’re Next” To Columbus Police Office
- Warning Graphic Video: Police Release Body Cam Footage of Teen Girl Killed By Police
- Apple, Google On Capitol Hill Today To Address Alleged Anti-Trust Issues in Apps Market
- CNN Exposé Reveals the Latest Media Corruption
- Bob Woodson: Libs Have Weaponized Race at the Expense of Low Income Blacks